Publications

Delivering an Outcomes-based NHS: Creating the Right Conditions

1 February 2017

This OHE Seminar Briefing summarises a seminar given by Dr Nicholas Hicks, Co-founder and Chief Executive of COBIC (Capitated Outcomes-Based Incentivised Care). Dr Hicks describes COBIC’s…

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

1 January 2017

PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. In a previous…

Policy Options for Formulary Development in Middle-income Countries

1 January 2017

PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. This report presents a framework…

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

5 July 2016

“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

12 January 2016

This Research Paper reports the views of 179 members of the UK general public about important aspects of health that they consider to be missing from the five dimensions of the EQ-5D instrument.

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

1 December 2016

This Research Paper reports on a literature review of trials using PFS as a surrogate for OS in oncology between 2012 and 2016; a workshop and…

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

1 December 2016

Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL.

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

1 December 2016

This Research Paper explores decisions by the National Institute for Health and Care Excellence (NICE) that new technologies are to be recommended in line with clinical practice (RiLCP). The authors qualitatively assess documentation associated with RiLCP decisions to create a framework to describe common themes, and assess the level of patient access associated with each RiLCP decision.

Uncertainty and Risk in HTA Decision Making

1 November 2016

The quality of decision-making in key public sector bodies dealing with resource allocation is a major determinant of their efficiency. One of the most difficult and contentious areas of decision-making is the way that uncertainty is dealt with.